<p><b>Objective</b>. To study the role of D₁DR and D₂DR dopamine receptors in the production of interleukins (IL) IL-6 and IL-1β by monocytes and macrophages in patients with relapsing-remitting multiple sclerosis (MS). <b>Materials and methods</b>. Ten patients with relapsing-remitting MS and 10 healthy subjects were investigated. Levels of IL-6 and IL-1β production were assessed in culture supernatants obtained from CD14⁺ monocytes or macrophages stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS). The role of dopamine receptors in the regulation of CD14⁺ monocytes and macrophages was studied by incubating cell samples in the presence of specific D₁DR or D₂DR antagonists, after which they were stimulated with IFN-γ/LPS. Cytokine levels in cell culture supernatants were measured by enzyme-linked immunosorbent assay. <b>Results</b>. IL-6 and IL-1β production levels by CD14⁺ monocytes and macrophages were similar in the two groups. Blockade of D₁DR suppressed cytokine production by both CD14⁺ monocytes and macrophages in both groups. In contrast, blockade of D₂DR enhanced cytokine production by CD14⁺ monocytes and had no effect on macrophages in both groups. <b>Conclusions</b>. Targeting of dopamine receptors may provide an additional mechanism of immunoregulation in MS able to exert both pro- and anti-inflammatory effects on innate immune response cells.</p>